Triglyceride deposit cardiomyovasculopathy: a rare cardiovascular disorder

Ming Li,† Ken-ichi Hirano,† Yoshihiko Ikeda, Masahiro Higashi, Chikako Hashimoto, Bo Zhang, Junji Kozawa, Koichiro Kobayashi, Yoshiaki Futsuuki, Nobuhiro Zaima, Satoshi Yamauchi, Rojeet Shrestha, Hiroshi Nakamura, Katsuhiro Kawaguchi, Eiryu Sai, Shu-Ping Hui, Yusuke Nakano, Akinori Sawamura, Tohru Inaba, Yasuhiko Sakanada, Yoko Yasui, Yasuyuki Nagaawa, Shintaro Kinugawa, Kazunori Shimada, Sohsuke Yamada, Daisaku Nakatani, Tomomi Ide, Tetsuya Amano, Hiroaki Naito, Hironori Nagasaka, Kunihisa Kobayashi, on behalf of the Japan TGCV study group

Abstract

Triglyceride deposit cardiomyovasculopathy (TGCV) is a phenotype primarily reported in patients carrying genetic mutations in PNPLA2 encoding adipose triglyceride lipase (ATGL) which releases long chain fatty acid (LCFA) as a major energy source by the intracellular TG hydrolysis. These patients suffered from intractable heart failure requiring cardiac transplantation. Moreover, we identified TGCV patients without PNPLA2 mutations based on pathological and clinical studies. We provided the diagnostic criteria, in which TGCV with and without PNPLA2 mutations were designated as primary TGCV (P-TGCV) and idiopathic TGCV (I-TGCV), respectively. We hereby report clinical profiles of TGCV patients. Between 2014 and 2018, 7 P-TGCV and 18 I-TGCV Japanese patients have been registered in the International Registry. Patients with I-TGCV, of which etiologies and causes are not known yet, suffered from adult-onset severe heart disease, including heart failure and coronary artery disease, associated with a marked reduction in ATGL activity and myocardial washout rate of LCFA tracer, as similar to those with P-TGCV. The present first registry-based study showed that TGCV is an intractable, at least at the moment, and heterogeneous cardiovascular disorder.

Keywords: Adipose triglyceride lipase, Atherosclerosis, Rare disease, Triglyceride-deposit cardiomyovasculopathy, Triglyceride metabolism

Triglyceride (TG) and orphan diseases

TG is a major energy source for mammals. In normal condition, TG is either received via the diet, or synthesized endogenously and stored in adipose tissues. When required, TG is hydrolyzed by various enzymes called lipases and releases long-chain fatty acid (LCFA), which is delivered to non-adipose tissues for the production of ATP. It has been known that the ectopic TG deposition in non-adipose tissues causes some orphan diseases. In 1953, Jordans reported two brothers with phenotype of skeletal myopathy and vacuolar formation of peripheral leukocytes, called Jordans’ anomaly [1]. Fifty years later, Fischer et al. found that this phenotype is associated with mutations in PNPLA2 [2] encoding adipose TG lipase (ATGL) [3, 4], an essential molecule located in cytoplasmic lipid droplets for the intracellular TG hydrolysis [5, 6], and designated this phenotype as neutral lipid storage disease with myopathy (NLSD-M). Clinical manifestations of NLSD-M appeared variable from mild to severe symptoms [7–13], which could be at least partially explained by function of mutated ATGL proteins

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Another phenotype of NLSD involving the skin was reported as NLSD with ichthyosis (NLSD-I) by Chanarin and Dorfman in the 1970s [15–17]. The genetic cause of NLSD-I was found to be mutations in ABHD5 encoding CGI-58, a co-enzyme of ATGL [18]. Using skin fibroblasts and iPSCs from patients with NLSDs, unique intracellular metabolism of TG has been extensively analyzed. These cell-biological experiments showed that cytoplasmic lipid droplets are dynamic cellular organelles interacting with ATGL, CGI-58, and other proteins, and could be a therapeutic target [19–23].

**Discovery of TG-deposit cardiomyovasculopathy (TGCV) with PNPLA2 (ATGL) mutation**

Since the early 1980s, patients with Jordans’ anomaly and severe heart failure (HF), though very rare, had been reported in Japan [24]. In the early 2000s, our institution started to take care of two patients with severe HF and vacuolar formation in peripheral leukocytes. HF was progressive and intractable, and a couple of years later, they became candidates for cardiac transplantation (CTx). Preoperative examination of their hearts exhibited dilated cardiomyopathy-like morphology in chest X-ray and ultrasonography; however, endomyocardial biopsy specimens showed neutral lipid deposition in cardiomyocytes [25]. When they underwent CTxs, pathological and biochemical analyses of their explanted hearts were performed, demonstrating that their coronary arteries showed unusual coronary atherosclerosis with TG deposition in endothelial and smooth muscle cells (SMCs). We named this novel phenotype as TGCV [26–28]. These patients were identified as homozygous for genetic mutations in PNPLA2 encoding ATGL, which is also known to be responsible for NLSD-M as described above [2].

**Postmortem analyses revealed undiagnosed individuals with TGCV**

Retrospective postmortem analyses of autopsied cases identified individuals with TGCV phenotype who had TG deposit in both myocardium and coronary arteries, as presented in Fig. 1. A 38-year-old man suddenly died...
irrespective of intensive treatment for coronary artery disease (CAD) and HF. His heart was heavy in weight and hypertrophied with multiple myocardial fibrous scars. Coronary arteries showed diffuse and concentric stenosis in multi-vessels. Biochemical analyses and imaging mass spectrometry showed TG deposition in both myocardium and coronary arteries [29, 30]. TG-deposit SMCs were observed in his renal and mesenteric arteries as well (data not shown). These data mimic genetic ATGL deficiency; however, the immunoreactive mass of ATGL was detected, and the genetic test using genomic DNA extracted from stored specimens showed no mutation in all exons and exon/intron boundaries of PNPLA2 gene (data not shown). In addition, pathological records showed that he did not have skeletal myopathy.

**Development of diagnostic methods for TGV**

The above postmortem studies suggested that it is difficult to diagnose TGV, and many undiagnosed patients should have died, which motivated us to develop diagnostic tools and methods for TGV. We reported that myocardial scintigraphy with iodine-123-β-methyl iodophenyl-pentadecanoic acid (BMIPP) [31, 32], a radioactive analogue of LCFA, was useful in detecting abnormal LCFA metabolism in patients with TGV [33, 34]. In addition, we reported the use of automated hematology analyzers to detect Jordans' anomaly in patients with PNPLA2 mutation [35–37]. Recently, we developed CT-based TG imaging to detect myocardial and coronary TG deposition [34, 38] and selective immunoinactivation assay to measure functional ATGL activities using peripheral leukocytes [39].

**Nomenclature, definition, and classification of TGV**

It is well known that disease nomenclature is made not only by their genotypes, but also by their phenotypes in many diseases and by discoverer’s names in some diseases. The nomenclature of TGV was made by its phenotype that TG accumulated in both myocardium and coronary arteries, resulting from abnormal intracellular metabolism of TG and LCFA (Fig. 2) [26–28]. ATGL is a known enzyme involved in the phenotypic expression of TGV. The Japan TGV study group provided the diagnostic criteria for TGV, in which TGV with and without PNPLA2 mutations was designated as primary TGV (P-TGV) and idiopathic TGV (I-TGV), respectively [40–42].

**Pathophysiology of TGV**

The pathophysiological schema of TGV is shown in Fig. 3. In normal condition (left panel, Fig. 3), LCFA are taken up through transporters and receptors such as CD36. Some are transported to the mitochondria for β-oxidation, and the remaining LCFA are utilized as a source of TG and rapidly hydrolyzed by intracellular lipases such as ATGL. In TGV (right panel, Fig. 3), LCFA are taken up and used to synthesize TG that cannot be hydrolyzed due to ATGL insufficiency, leading to energy failure and lipotoxicity with massive TG accumulation [28, 43]. It is emphasized that TG-deposit atherosclerosis is an important characteristics of TGV [44] and distinct from usual cholesterol-deposit atherosclerosis, because the former showed diffuse and concentric narrowing formed by TG-deposit SMCs, whereas the latter showed discrete and eccentric stenosis initiated by the response to injury in the endothelium and...
accumulation of cholesterol-laden macrophages [45] (Fig. 4). We reported that TG-deposit SMCs and endothelial cells had pro-inflammatory and vulnerable phenotype in vitro [46, 47].

A clinical case presentation of I-TGCV
A 58-year-old woman was referred to our hospital due to sudden chest tightness with ST-segment elevation in the electrocardiogram, followed by cardiopulmonary arrest. Under the diagnosis of acute myocardial infarction, she underwent coronary artery bypass grafting (CABG). Past history included type 2 diabetes mellitus requiring insulin treatment and hemodialysis. Cytoplasmic vacuoles in her peripheral polymorphonuclear leukocytes were observed less frequently (< 10% of neutrophils), compared with that in genetic ATGL deficiency (panel A in Fig. 5). ATGL activity in peripheral leukocytes was very low, comparable to that of genetic ATGL deficiency, as shown in Table 1. Myocardial washout rate (WOR) of BMIPP was defective in scintigraphy (panel B in Fig. 5). Pathological analyses of endomyocardial biopsy specimens demonstrated numerous vacuoles filled with stained lipid but positive reactivity for ATGL in cardiomyocytes and adipocytes (right, panel C in Fig. 5). Coronary CT angiogram showed diffuse narrowing coronary arteries, and in TG imaging [25], outside-in involvement of diffuse and abundant lipid components expressed as low CT numbers was seen within the wall in a peninsula pattern (arrows in panel D in Fig. 5). Her laboratory data and imaging tests were similar to those observed in TGCV with genetic ATGL deficiency, except for the conserved expression of ATGL protein in the myocardium. However, it is noted that the case was clinically distinct from genetic ATGL deficiency because there was no skeletal myopathy and no elevation of MM type creatine kinase. Genetic tests showed no mutations or substitutions in any of the exons or intron/exon boundaries of genes encoding ATGL, 1-acylglycerol-3-phosphate O-acyltransferase, hormone-sensitive lipase, or GOS2 (data not shown).

Clinical characteristics of P- and I-TGCV
Table 1 shows the clinical characteristics of 7 and 18 patients with P- and I-TGCV, respectively, registered to the international registry for NLSD and TGCV between February 2014 and March 2018 in Japan. Both TGCV types were adult onset with chest pain at rest or dyspnea and palpitation. Most patients with either types of TGCV developed severe HF or CAD with diffuse narrowing multivessel lesions or both. Myocardial metabolism of LCFA, detected by WOR of BMIPP and ATGL activities in peripheral leukocytes, was reduced in both TGCV types. Most patients with P-TGCV developed intractable and critical HF, as reported recently [26, 48, 49]. Two of them underwent CTx [26, 48]. Many patients with I-TGCV required percutaneous coronary intervention and CABG. As comorbidity, neither type of TGCV had skin lesions, which suggests that TGCV is not associated with NLSD-I. All patients with P-TGCV had skeletal myopathy, whereas none of those with I-TGCV did. Five of 7 and 3 of 18 registered patients with P- and I-TGCV, respectively, died.

Differential diagnosis of TGCV
Myocardial disorders such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, mitochondrial cardiomyopathy, alcoholic heart disease, and metabolic myocardial disorders (e.g., Fabry disease, Pompe disease, cholesteryl ester storage disease) need to be differentiated from TGCV [41, 42]. Furthermore, known diabetic and metabolic heart diseases need to be differentiated from TGCV. One is diabetic cardiomyopathy, which was originally defined as cardiomyopathy without significant stenosis in epicardial coronary arteries [50]. Another concept is epicardial fat accumulation, which is the overdeposition of TG in physiological tissues. TGCV is distinct from these two entities because TGCV is characterized by the ectopic deposition of TG in the cardiomyocytes and SMCs with apparent involvement of epicardial coronary arteries, as shown in Figs. 1 and 5.

Academia-initiated development of specific treatment for TGCV
We found that the chow with tricaprin, TG form of capric acid, improved LCFA metabolism, lipid deposition, cardiac function, and life span in ATGL-targeted mice [4], raising a therapeutic hypothesis that capric acid may be an alternative energy source and reduce TG deposition and lipotoxicity in TGCV [51]. Based upon
these data, the Osaka University Hospital manufactured GMP-graded capsules containing the active gradients called CNT-01. We developed the assay to measure plasma capric acid levels [52, 53]. After finishing toxicity tests using rats and dogs required, we are finally conducting investigator-initiated clinical trials.

**Comparison between NLSD-I, NLSD-M, and TGCV**

As mentioned above, the nomenclature of TGCV was made by its phenotype that TG accumulated in both myocardium and coronary arteries, resulting from abnormal intracellular metabolism of TG and LCFA (Figs. 2 and 3). As described in the first paragraph in this letter, there have been known related disorders; NLSD-M and NLSD-I. Figure 6 shows the comparison of phenotype and genotype between TGCV and NLSDs. NLSD-M and NLSD-I are caused by mutations in *PNPLA2* and *ABHD5*, mainly involved in the skeletal muscle and skin, respectively. Genotype of P-TGCV is known to be *PNPLA2* mutation which is responsible for NLSD-M as well.
| Table 1 Patients’ characteristics of Primary and Idiopathic TGCV |
|---------------------------------------------------------------|
|                                                              |
| **General Status**                                            |
|                                                              |
| Age (years)                                                   | 55.7 ± 12.7 | 64.6 ± 14.7 |
| Sex (female, male) (n)                                        | (2, 5)      | (9, 9)      |
| BMI (kg/m²)                                                   | 19.4 ± 3.4  | 25.4 ± 5.0  |
| Family history for CVD                                        | 7           | 13          |
| **ATGL expression**                                           |
|                                                              |
| PNPLA2 mutation                                               | Yes         | No**        |
| ATGL activities in leukocytes (nmol/h/mg)*                    | 5.3 ± 8.3   | 12 ± 9      |
|    (reference value 52 ± 13 nmol/h/mg)                       |             |             |
| Vacuole formation in polymorphonuclear leukocytes (%)         | ~ 100%      | < 10%       |
| **Heart disease**                                             |
|                                                              |
| Mean age of symptom onset (years)                            | 37.7 ± 9.2  | 55.9 ± 12.5 |
| Angina at rest (n)                                           | 3           | 10          |
| Dyspnea or palpitation (n)                                   | 4           | 8           |
| **Clinical diagnosis at registration**                        |
|                                                              |
| Angina pectoris                                              | 1           | 13          |
|    (rest, effort) (n)                                        | (1,0)       | (11, 2)     |
| Heart failure (n)                                            | 5           | 8           |
| Critical arrhythmia (n)                                      | 4           | 1           |
| History of myocardial infarction (n)                         | 0           | 4           |
| NYHA classification (I, II, III, IV) (n)                     | (1, 1, 2, 3)| (2, 5, 11, 0)|
| **Coronary angiography or CT angiogram**                     |
|                                                              |
| Affected branch (single vessel, multivessels) (n)             | (0, 5)      | (4, 14)     |
| Diffuse narrowing (n)                                        | 5           | 18          |
| Washout rate in BMIPP scintigram (%)                         | ~3.2 ± 4.8  | 1.4 ± 8     |
|    (reference value 19.4 ± 3.2%)                             |             |             |
| **Treatment history**                                        |
|                                                              |
| Percutaneous coronary intervention (n)                       | 0           | 7           |
| Coronary artery bypass grafting (n)                          | 0           | 5           |
| Cardiac transplantation (n)                                  | 2           | 0           |
| **Comorbidity**                                               |
|                                                              |
| Skin lesions (n)                                             | 0           | 0           |
| Skeletal myopathy (n)                                        | 7           | 0           |
| Diabetes mellitus (n)                                        | 2           | 15          |
| **Outcome**                                                  |
|                                                              |
| Death (n)                                                     | 5           | 3           |
|    (before, after registration)                              | (3, 2)      | (2, 1)      |

*Three patients with P-TGCV and fourteen with I-TGCV were enrolled
We did not have opportunity for the measurement in the remaining four patients with P-TGCV and four with I-TGCV
**Two patients were dismissed before the genetic analysis
The Japan TGCV study group certified I-TGCV according to the diagnostic guideline
Abbreviations: CT Computed tomography, CVD Cardiovascular disease, TGCV Triglyceride deposit cardiomyovascularopathy
Issues to be resolved
The following points are important focus for future researches:

1. Possible clinical continuum between P-TGCV and NLSD-M
   As mentioned above, both P-TGCV and NLSD-M is caused by genetic ATGL deficiency. It would be of interest to know whether patients with NLSD-M have TG-deposit atherosclerosis, which is the important feature for P-TGCV.

2. Etiologies of I-TGCV and its prevalence in countries other than Japan
   As shown in Table 1, 13 out of 18 patients with I-TGCV had family history of cardiovascular disease, suggesting that any genetic factors might be involved in the pathogenesis of I-TGCV. The mechanism underlying downregulation of ATGL activities of I-TGCV and possible involvement of other lipases and related enzymes is of significance to elucidate. In order to elucidate these issues, the development of screening methods for the diagnosis of I-TGCV is under way in our laboratory.

Conclusions
TGCV is a severe cardiovascular disorder named by its phenotype of cardiomyovascular TG deposition, of which etiologies seem heterogeneous.

Methods

1. Pathological, laboratory, and clinical imaging
   Standard procedures were performed as described (please see legends of Figs. 1 and 5).

2. International registry for NLSD/TGCV
   On the World Rare Disease Day 2014, we launched the international registry for neutral lipid storage diseases, TG-deposit cardiomyovasculopathy, and related disorders (Clinical Trial.gov. NCT02830763). The present patients with TGCV were registered according to the study protocol after obtaining written consent. The protocol was approved by the Osaka University Hospital Ethical Committee (approval no. 13204).

Fig. 6 Relationship between TGCV and NLSDs. Comparison of phenotype and genotype between NLSD-I, NLSD-M and TGCV

| Phenotype | NLSD-I | NLSD-M | TGCV |
|-----------|--------|--------|------|
| Genotype  | ABHD5  | PNPLA2 | PNPLA2 |
|           | mutation| mutation| mutation|
| Major tissue involved | Skin | Skeletal muscle | Heart, Vessel |

Abbreviations
ATGL: Adipose triglyceride lipase; BMIPP: Iodine-123-β-methyl iodophenylpentadecanoic acid; CAGB: Coronary artery bypass grafting; CAD: Coronary artery disease; CTA: CT angiograms; CTx: Cardiac transplantation; HF: Heart failure; Hu: Hounsfield unit; LCFA: Long-chain fatty acid; NLSD: Neutral lipid storage disease; NLSD-I: NLSD with ichthyosis; NLSD-M: NLSD with myopathy; SMCs: Smooth muscle cells; TG: Triglyceride; TGCV: Triglyceride-deposit cardiomyovasculopathy; WOR: Washout rate

Acknowledgments
The authors thank Dr. Kosuke Tsukamoto for playing a part in constructing the international registry. The authors would like to thank Ms. Mao Ishikawa and Yoshie Yabe for their excellent secretarial work.

Funding
This study was partially supported by research grants from the Ministry of Health, Labour and Welfare and the Japan Agency of Medical Research and Development (A-MED; grant no. 17ek0109092h0003), Nihon Medi-Physics Co., Ltd., and the Tochino Foundation to KH.

Availability of data and materials
The datasets generated and/or analyzed in the current study are available from the corresponding author on reasonable request.

Authors’ contributions
ML wrote the manuscript and contributed to data analyses and discussion. KH designated the research concept and contributed to the discussion and writing of the manuscript. YoI performed autopsy for the undiagnosed case (Fig. 1), collected data, and contributed to the discussion and writing of the manuscript. KH and JK took care of the clinically identified I-TGCV case (Fig. 5). CH, BZ, JK, Ksu, HM, ASu, YH, AT, Yal, Kgg, MH, YF, NZ, SYamag, KS, and SYamad collected data and contributed to the discussion. HNak, Kk, ES, S-PH, YNak, Tin, YS, Y Yasui, YNag, ASa, SK, KSh, HH, DN, Tid, TA, HNai, and HNag interpreted and discussed the data. KuK designated the registry, collected data, and contributed to the discussion. All the authors have read and revised the manuscript and approved the final manuscript.

Ethics approval and consent to participate
The protocol of the international registry was approved by the Osaka University Hospital Ethical Committee (Approved No. 13204).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Laboratory of Cardiovascular Disease, Novel, Non-invasive, and Nutritional Therapeutics and Triglyceride Research Center (TGRC), Graduate School of Medicine, Osaka University, 6-2-4, Furuedai, Suita, Osaka 565-0874, Japan.
2Department of Pathology, National Cerebral and Cardiovascular Center, 5-7-1, Fujishirodai, Suita, Osaka 565-8565, Japan.
3Department of Radiology, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuo-ku, Osaka 540-0006, Japan.
4Department of Biochemistry, Fukuoka
University Medical School, 7–45–1, Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. 3. Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2–2, Yamaadoka, Suita, Osaka 565-0871, Japan. 4. Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, 1–1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan. 5. Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1–8–1, Inohana, Chuo-ku, Chiba 260-8670, Japan. 6. Division of Molecular Brain Science, Kobe University Graduate School of Medicine, 7–5–1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. 7. Department of Applied Biological Chemistry, Graduate School of Agriculture, Kindai University, 3327–204, Nakamachi, Nara 631-8505, Japan. 8. Faculty of Health Sciences, Hokkaido University, Kita-12, Nishi-5, Sapporo 006-0812, Japan. 9. Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, 3–1, Aoyama-cho, Kure, Hiroshima 737-0023, Japan. 10. Department of Cardiovascular Medicine, Komaki City Hospital, 1–20, Jobushiri, Komaki, Aichi 485-8520, Japan. 11. Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, 2–1–1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. 12. Department of Cardiology, Aichi Medical University, 1–1, Yazaokakarimata, Nagakute, Aichi 480-1195, Japan. 13. Department of Internal Medicine, Division of Kidney and Dialysis, Hyogo College of Medicine, 1–1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. 14. Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan. 15. Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 1–1 Daigaku, Uchinada, Ishikawa 920-0293, Japan. 16. Department of Internal Medicine, Division of Infection Control and Laboratory Medicine, Kyoto Prefectural University of Medicine, 465, Kaji-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. 17. Faculty of Human Life Science, Osaka City University, 3–3–138, Sugimoto, Sumiyoshi-ku, Osaka 558-8585, Japan. 18. Department of Internal Medicine, Division of Kittani and Laboratory Medicine, Kyoto Prefectural University of Medicine, 30–1 Ogihaguchikami-cho, Tabashi-ku, Tokyo 173-8610, Japan. 19. Center for Global Health, Department of Medical Innovation, Osaka University Hospital-AF Center of Medical Innovation and Translational Research, 2–2 Yamanada, Suita, Osaka 565-0871, Japan. 20. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2–2 (A8) Yamanada, Suita, Osaka 565-0871, Japan. 21. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyushu University, 3–1–1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. 22. Department of Radiology, Nippon Life Hospital, 2–1–54, Enokojima, Nishi-ku, Osaka 550-0006, Japan. 23. Department of Pediatrics, Takarazuka City Hospital, 4–5–1, Obama, Takarazuka, Hyogo 665-0827, Japan. 24. Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushu Hospital, 1–1–1, Zokumyoin, Chikushu, Fukuoka 819-8502, Japan.

Received: 2 January 2019 Accepted: 1 May 2019
Published online: 11 June 2019

References

1. Jordans GH. The familial occurrence of fat containing vacuoles in the leukocytes diagnosed in two brothers suffering from dystrophia musculorum progressiva (ERB.). Acta Med Scand. 1953;145(6):419–23.
2. Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, Negre-Salvayre A, Lathrop M, Salvayre R. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet. 1997;20(1):55–7.
3. Missaglia S, Maggi L, Mora M, Giberti S, Blasevic F, Agostoni P, Morandi L, Mora T, Cavagnini D, Santorelli FM, Gerevini S, Taviani D. Late onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement. Neuro muscular Disord. 2017;27(5):481–6.
4. Lepore J, Stojkovic T, Basseg, Carlig PG, Clement K, Wahn K, Petit FM, Eymard B, Carlier RT. Neutral lipid storage disease with myopathy: a whole-body-nuclear MR and metabolic study. Mol Genet Metab. 2015;115(2):165–7.
5. Negre-Salvayre A, Radom J, Douste-Blazy L. Independence of triacylglycerol-esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet. 2001;69(1):96–106.
6. Cassandrini D, Santorelli FM, Gerevini S, Taviani D. Orphanet Journal of Rare Diseases (2019) 14:134
7. Heldmaier G, Maier R, Theussl C, Eder S, Kratky D, Wagner EF, Klingenspor M, Gruenberger R, Riedere M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Wollenberg A, Verret JL, Weissenbach J, Ozguc M, Lathrop M, Prudhomme JF, Fischer J. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet. 2001;69(5):1002–12.
8. Salvayre R, Negre A, Radorn J, Douste-Blazy L. Independence of triacylglycerol-containing compartments in cultured fibroblasts from Wolman disease and multisystemic lipid storage myopathy. FEMS Lett. 1989;250(135):9–5.
9. Hilaire N, Salvayre R, Their JC, Bonaffie MJ, Negre-Salvayre A. The turnover of cytoplasmic triacylglycerols in human fibroblasts involves two separate acyl chain length-dependent degradation pathways. J Biol Chem. 1995;270(10):2707–34.
10. Nakamura K, Hirano K, Wu SM. iPSC cell modeling of cardiometabolic diseases. J Cardiovasc Transl Res. 2013;6(1):46–53.
11. Salvayre D, Missaglia S, Castagnetta N, Degiron D, Pennisi M, Coleman RA, Dell’Era P, Mota C, Angelini C, Coviello DA. Generation of induced pluripotent stem cells as disease modelling of NLSDM. Mol Genet Metab. 2017;121(1):28–34.
12. Missaglia S, Coleman RA, Morekoon AH, Taviani D. Neutral lipid Storage diseases due to novel PNPLA2 mutations causing total loss of lipase activity: a new disorder of lipid metabolism. Br Med J. 1975;1(5957):553–5.
13. Ilg RA, Rhoads JM, Coleman RA. Neutral lipid storage disease with fatty liver and cholestasis. J Pediatr Gasteroenterol Nutr. 1997;25(5):541–5.
14. Tavian D, Missaglia S, Redaelli C, Pennisi EM, Invernici G, Weisslofski RA, Mainwaid R, Arca M, Coleman RA. Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function. Hum Mol Genet. 2012;21(24):5318–28.
15. Dorfman ML, Hershko C, Eisenberg S, Sagher F. Ichthyosiform dermatomusculo-skeletal syndrome: a new disorder of lipid metabolism. Br Med J. 1975;1(5957):553–5.
16. Lathrop M, Salvayre R. The phenotypic spectrum of neutral lipid storage myopathy with systemic lipidosis. Arch Dermatol. 1974;110(2):261–8.
17. Chanarin I, Patel A, Slavin G, Ellis AJ, Andrews TM, Stewart G. Neutral-lipid storage disease: a new disorder of lipid metabolism. Br Med J. 1975;1(5957):553–5.
18. Salvayre R, Negre A, Radorn J, Douste-Blazy L. Independence of triacylglycerol-containing compartments in cultured fibroblasts from Wolman disease and multisystemic lipid storage myopathy. FEMS Lett. 1989;250(135):9–5.
19. Salvayre R, Negre A, Radorn J, Douste-Blazy L. Independence of triacylglycerol-containing compartments in cultured fibroblasts from Wolman disease and multisystemic lipid storage myopathy. FEMS Lett. 1989;250(135):9–5.
20. Salvayre R,Negre A, Radorn J, Douste-Blazy L. Independence of triacylglycerol-containing compartments in cultured fibroblasts from Wolman disease and multisystemic lipid storage myopathy. FEMS Lett. 1989;250(135):9–5.
27. Hirano K. A novel clinical entity: triglyceride deposit cardiomyovasculopathy. J Atheroscler Thromb. 2009;16(5):702–7.
28. Hirano K, Tanaka T, Ikeda Y, Yamaguchi S, Zaima N, Kobayashi K, Suzuki A, Sakata Y, Sakata Y, Kobayashi K, Toda T, Fukushima N, Ishibashi-Ueda H, Tavian D, Nagasaki H, Hui SP, Chiba H, Sawa Y, Hon M. Genetic mutations in adipose triglyceride lipase and myocardial up-regulation of peroxisome proliferated activated receptor-gamma in patients with triglyceride deposit cardiomyovasculopathy. Biochem Biophys Res Commun. 2014;443:574–9.
29. Ikeda Y, Zaima N, Hirano K, Mano M, Kobayashi K, Yamada S, Yamaguchi S, Suzuki A, Kanazaki H, Hamasaki T, Kotori J, Kato S, Nagasaki H, Setou M, Ishibashi-Ueda H. Coronary triglyceride deposition in contemporary advanced diabetics. Pathol Int. 2014;64(7):325–35.
30. Nakanishi T, Kato S. Impact of diabetes mellitus on myocardial lipid deposition: an autopsy study. Pathol Res Pract. 2014;210(12):1018–25.
31. Goodman MM, Kirsch G, Knapp FF Jr. Synthesis and evaluation of radiodiutated terminal p-iodophenyl-substituted alpha- and beta-methyl-branched fatty acids. J Med Chem. 1984;27:390–7.
32. Kunita C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N, Kawai H, Kaneko M. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med. 1992;33(11):136–13.
33. Hirano K, Ikeda Y, Sugimura K, Sakata Y. Cardiomyocyte steatosis and defective washout of iodine-123 beta-methyliodophenylpentadecanoic acid in genetic deficiency of adipose triglyceride lipase. Eur Heart J. 2015;36(9):580.
34. Higashi M, Ikeda Y, Miyashita H, Zaima N, Suzuki A, Li M, Kobayashi K, Naito H, Hirano K. Imaging modalities for triglyceride deposit Cardiomyovasculopathy. Ann Nucl Cardiol. 2017;3(1):104–102.
35. Suzuki A, Nagasaki H, Ochi Y, Kobayashi K, Nakamura H, Nakatani D, Yamaguchi Y, Yamaki S, Wada A, Shirata Y, Hui SP, Toda T, Kuroda H, Chiba H, Hirano K. Peripheral leukocyte anomaly detected with routine automated hematology analyzer sensitive to adipose triglyceride lipase deficiency manifesting neutral lipid storage disease with myopathy/triglyceride deposit cardiomyovasculopathy. Mol Genet Metab Rep. 2014;2:49–50.
36. Inaba T, Ishizuka K, Suzuki A, Yasua S, Saito K, Kodama M, Hamada M, Hongo F, Fujita N, Hirano K. Basic utility of Pentra series automated hematology analyzer for screening Jordans’ anomaly. Int J Lab Hematol. 2017;39:e1–3.
37. Inaba T, Ishizuka K, Suzuki A, Yasua S, Saito K, Kodama M, Hongo F, Fujita N, Hirano K. Comparison for neutrophil distribution patterns in Jordans’ anomaly among major automated hematology analyzers. Int J Lab Hematol. 2018;40:e78–81.
38. Kozawa J, Higashi M, Shihomura I, Hirano K. Intractable Coronary Artery Disease in a Patient with Type 2 Diabetes Presenting With Triglyceride Deposit Cardiomyovasculopathy. Diabetes Care. 2019;42(5):983–6.
39. Takagi A, Ikeda Y, Kobayashi K, Kobayashi K, Ikeda Y, Kozawa J, Miyashita H, Li M, Hashimoto C, Hara Y, Yamaguchi S, Suzuki A, Toda T, Nagasaki H, Hirano K. Newly developed selective immunoinactivation assay revealed reduction in adipose triglyceride lipase activity in peripheral leucocytes from patients with idiopathic triglyceride deposit cardiomyovasculopathy. Biochem Biophys Res Commun. 2018;495(1):564–56.
40. Hirano K. Triglyceride deposit cardiomyovasculopathy, TGCV-To overcome this intractable disease one day sooner. Nihon Naika Gakai Zasshi. 2017;106:2385.
41. Miyashita H, Hashimoto C, Ikeda Y, Li M, Nakano Y, Kozawa J, Sai E, Nagasaki Y, Sugimura K, Kinugawa S, Kawaguchi K, Shimada K, Ide T, Amato T, Higashi M, Inaba T, Nakamura H, Kobayashi K, Hirano K. Diagnostic criteria and severity score for triglyceride deposit cardiomyovascularopathy. Ann Nucl Cardiol. 2018;1(4):194–100.
42. Hirano K, Li M, Ikeda Y. Triglyceride deposit cardiomyovascularopathy. In: Ohashi T, Tsukahawa H, Ramiez F, Barber C, Otsuka F, editors. Human Pathobiocemistry. Luxembourg: Springer, Singapore; 2018. p. 111–9.
43. Hara Y, Kawanishi N, Hirano K, Hashimoto Y, Adachi J, Watanabe S, Tomonaga T. Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovascularopathy. Orphanet J Rare Dis. 2013;8:197.
44. Ikeda Y, Hirano K, Fukushima N, Sawa Y. A novel type of human spontaneous coronary atherosclerosis with triglyceride deposition. Eur Heart J. 2014;35(13):875.
45. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115–26.
46. Inoue T, Kobayashi K, Inoguchi T, Sonoda N, Fuji M, Maeda Y, Fujimura Y, Miura D, Hirano K, Takayanagi R. Reduce expression of adipose triglyceride lipase enhances tumor-necrosis factor alpha-induced intercellular adhesion molecule-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappa B. J Biol Chem. 2011;286:20465–53.
47. Lin Y, Chiba S, Suzuki A, Yamaguchi S, Nakanishi T, Matsumoto H, Ikeda Y, Ishibashi-Ueda H, Hirano K, Kato S. Vascular smooth muscle cells isolated from adipose triglyceride lipase-deficient mice exhibit distinct phenotype and phenotypic plasticity. Biochem Biophys Res Commun. 2013;434(3):534–40.
48. Higashi M, Hirano K, Kobayashi K, Ikeda Y, Issiki A, Otsuka T, Suzuki A, Yamaguchi S, Zaima N, Hamada S, Hanada H, Suzuki C, Nakamura H, Nagasaki H, Miyata T, Miyamoto Y, Kobayashi K, Naito H, Toda T. Distinct cardiac phenotype between two homozygotes born in a village with accumulation of a genetic deficiency of adipose triglyceride lipase. Int J Cardiol. 2015;192:30–2.
49. Kaneko K, Kuroda H, Izumi R, Tateyama M, Kato M, Sugimura K, Sakata Y, Ikeda Y, Hirano K, Aoki M. A novel mutation in PNPLA2 causes neutral lipi storage disease with myopathy and triglyceride deposit cardiomyovascularopathy: a case report and literature review. Neuromuscul Disord. 2014;24(7):634–41.
50. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. A new type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30:595–602.
51. Suzuki A, Yamaguchi S, Li M, Hara Y, Miyashita H, Ikeda Y, Zhang B, Higashi M, Ikeda Y, Takagi A, Nagasaka H, Kobayashi K, Magata Y, Aoyama T, Hirano K. Tricarbin rescues myocardial abnormality in a mouse model of triglyceride deposit Cardiomyovascularopathy. J Oleo Sci. 2018;89:93–9.
52. Shrestha R, Hui SP, Imai H, Hashimoto S, Uemura N, Takeda S, Fuji H, Suzuki A, Yamaguchi S, Hirano K, Chiba H. Plasma capric acid concentrations in healthy subjects determined by high-performance liquid chromatography. Ann Clin Biochem. 2015;52:588–96.
53. Shrestha R, Hirano K, Suzuki A, Yamaguchi S, Miura Y, Chen YF, Mizuta M, Chiba H, Hui SP. Change in plasma total, esterified and non-esterified capric acid concentrations during a short-term oral administration of synthetic tricaprin in dogs. Anal Sci. 2017;33:297–303.